About Medicorp Technologies
Medicorp Technologies Ltd. (now merged into Matrix Laboratories) is a manufacturer of bulk drugs, including the popular Acyclovir. It also manufactures anti-viral, anti-fungal, anti-ulcer and cardiac drugs. Medicorp's core competency lies in the anti-infective, central nervous system and cardiovascular therapeutic segments. Sensing synergies between Matrix Laboratories and Medicorp in the manufacture of bulk drugs, Medicorp merged into Matrix labs.
Missing: Medicorp Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Medicorp Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Medicorp Technologies Frequently Asked Questions (FAQ)
What is Medicorp Technologies's latest funding round?
Medicorp Technologies's latest funding round is Unattributed.
Who are the investors of Medicorp Technologies?
Investors of Medicorp Technologies include ICICI Venture.
Who are Medicorp Technologies's competitors?
Competitors of Medicorp Technologies include Evotec SE, Arena Pharmaceuticals, Charleston Laboratories, Putney, Xytis and 9 more.
Compare Medicorp Technologies to Competitors
Xytis is engaged in the development of central nervous systems drugs.
Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.
The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.
Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Ciblex Corporation is engaged in the development of drugs that impact protein trafficking for use in proliferative disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.